Global Smoking Cessation Drugs Market Set To Grow To $3.6bn By 2022

08 August 2018
Pharma

Visiongain’ has launched a new pharma report Global Smoking Cessation Drugs Market Forecast 2017-2027: NRT, Non-nicotine Pharmacotherapy, Prescription Drugs, OTC Drugs

This report is intended to provide an in-depth analysis of the latest trends prevailing in the Global Smoking Cessation Drugs Market and its growth and development in the next decade. The changing demographics of the world population, developing infrastructure, emerging economies, consumer spending behaviour, per capita income, macroeconomic factors, rising GDPs, and the reformation in laws and regulations are trend setting factors, which will affect the market. Nicotine replacement therapy and pharmacotherapy are approved to aid in smoking cessation. While nicotine replacement products can be available as prescription drugs or over-the-counter medicines, pharmacotherapeutic treatments are available only by prescription

The lead analyst of the report commented “The Global Smoking Cessation Drugs market is influenced by several factors during the forecast period. The market is influenced by decreasing prevalence of tobacco smoking, increasing awareness about diseases and comorbidities fuelled by tobacco smoking, increasing regulation of vaping products market, availability of multiple dosage forms of NRT products, as well as various national and international level policies being adopted by a growing number of countries to combat tobacco smoking”

Leading companies featured in the report include Pfizer, Johnson & Johnson (J&J), GlaxoSmithKline (GSK), 22nd Century Group, Inc, Chrono Therapeutics, Cerecor Inc, Selecta Biosciences, Embera NeuroTherapeutics, CV Sciences

Notes for Editors
If you are interested in a more detailed overview of this report, please send an e-mail to sara.peerun@visiongainglobal.com or call her on +44 (0) 207 336 6100

About visiongain
Visiongain is one of the fastest-growing and most innovative independent media companies in Europe. Based in London, UK, visiongain produces a host of business-to-business reports cusing on the automotive, aviation, chemicals, cyber, defence, energy, food & drink, materials, packaging, pharmaceutical and utilities sectors.

Visiongain publishes reports produced by analysts who are qualified experts in their field. Visiongain has firmly established itself as the first port of call for the business professional who needs independent, high-quality, original material to rely and depend on.

Recent News

Visiongain Publishes Viral Vectors & Plasmid DNA Manufacturing Market Report 2021-2031

Due to increases in the therapies in progress, the dosages provided, & the patient populations targeted, viral vector production capacity has become increasingly reduced in recent years. The condition is aggravated by COVID-19.

03 December 2020

Read

Visiongain Publishes Drugs of Abuse Testing Market Report 2021-2031

Drugs Abuse has risen very significantly in few last year as compared to previous once and expected to continuously rise over the forecast period. The increase in the drugs abuse creates a huge demand for the drugs of abuse testing products.

03 December 2020

Read

Visiongain Publishes Controlled Substance Market Report 2021-2031

Continuous increasing prevalence of chronic pain is increasing demand for controlled substance as treatment for Chronic pain. Due to which increasing prevalence of chronic pain around the world is working as a driver for the controlled substance market.

03 December 2020

Read

Visiongain Publishes Companion Animal Diagnostics Market Report 2021-2031

All regions are facing rapid growth in the companion animal population. Companion animal are at high risk of developing various diseases for which companion animal require timely diagnosis for the identification, detection and treatment for life causing diseases.

03 December 2020

Read

Kelloggs
3m
Thales
Shell
TEVA
Lockheed-Martin
Pfizer
Raytheon
Halliburton
Du-Pont
Honeywell
Daimler
BASF
Bayer
BP
BAE-Systems
Unilever